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injury in a patient receiving interferon beta-1a treatment.
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issecting cellulitis (DSC) is a chronic inflam-
matory disease of hair follicles. Affected
patients develop painful scalp nodules and
sinus tracts. Although the precise cause is unknown,
it is proposed that collapse of the hair follicle wall
secondary to defective follicular support plays a role
not only in DSC but also in conditions that make
up the so-called follicular occlusion tetrad: DSC,
hidradenitis suppurativa (HS), acne conglobata, and
pilonidal cysts.1
Altered innate and adaptive immune responses
may also be involved in the pathogenesis of DSC and
HS.2 In HS, increased levels of tumor necrosis factor
(TNF)-alfa, interleukin (IL)-10, IL-1b, and IL-17a
have been documented. Treatments that inhibit the
action of TNF-alfa, such as infliximab and adalimu-
mab, are helpful for many patients with DSC and
HS.3-5 How other immune mediators affect these
diseases is not well understood.
Here we present a case of DSC developing at site
of trauma in a patient receiving interferon beta-1a
therapy for multiple sclerosis. This case provides
further insight into the possible pathogenesis of
DSC.
CASE REPORT
A 25-year-old man of Middle Eastern descent
presented with a 7-month history of scalp nodules,
abscesses, and sinus tracts with purulent discharge.
Affected areas were predominantly left-sided and the
area of involvement had slowly increased in size
over time (Fig 1). Biopsy specimen confirmed the
diagnosis of DSC.
Further history revealed that the scalp papules
and papulonodules first developed at the site of a
previous traumatic injury to the scalp. The patientthe University of Toronto Hair Clinic, Women’s College
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oronto.ca.was in a car accident 7 years prior and at that time
required scalp stitches. The area, however,
healed completely with no residual pain, itching,
redness, discharge, or obvious hair loss. Medical
history included a 3-year history ofmultiple sclerosis.
Interferon beta-1a (Rebif, EMD Serono, Mississauga,
ON) subcutaneous injections were started 6 months
before the development of DSC. The patient was also
a smoker.
Scalp swabs were negative for bacteria. The
patient partially responded to treatment withJAAD Case Reports 2015;1:303-4.
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304 Donovanisotretinoin 1 mg/kg. Further reduction and flat-
tening of the lesions was achieved with an 8-week
tapering course of prednisone (40 mg to 0 mg,
reducing 5 mg per week) and cephalexin.
DISCUSSION
DSC is an uncommon suppurative scarring alope-
cia that typically affects young men. Although the
precise pathogenesis of DSC is unknown, it is hypoth-
esized to be related to follicular occlusion, secondary
infection, and deep-seated inflammation. Of all the
cytokines and chemokines studied inHS andDSC, the
best understood role is for TNF-alfa; TNF-inhibitory
medications are helpful in both DSC and HS.3,4
The short duration between initiation of inter-
feron beta-1a therapy and the development of DSC
supports a possible association. Interferon (IFN) beta
plays an important role in the innate immune system.
It functions as a counter-regulatory cytokine and
opposes the production of proinflammatory cyto-
kines. For example, IFN beta inhibits TNF-alfa
secretion and this would likely be beneficial to
inhibit the development or progression of DSC.
However, IFN also enhances IL-10 production,
which would theoretically be detrimental and pro-
mote development of DSC-type lesions.5 IFN may
also impair neutrophils, which would be significant
given that impaired neutrophilic function may be
contributory to the pathogeneis.6 There have been
anecdotal reports submitted to the US Food and
Drug Administration of HS-type conditions devel-
oping in patients using various types of interferon
beta-1a therapy7,8; however the strength of these
associations is not clear, nor are the precise details of
each of the cases. DSC has not been previously
reported with interferon beta-1a therapy to our
knowledge.
Further study is needed to determine if alterations
in the immune system induced by interferon beta-1a
are associated with follicular occlusion in predis-
posed patients. It appears that the specific immune
system changes that occur in patients with multiple
sclerosis are not commonly associated with the
entities of the follicular occlusion tetrad. To the
author’s knowledge, DSC has not been reported
with MS. However, HS has been reported in associ-
ation with multiple sclerosis in 1 report.9
The development of DSC precisely at the site
of the patient’s traumatic injury suggests a role
for trauma. However, the role of trauma in thepathogenesis of DSC is unknown. It appears, at least
for HS, that reducing trauma is important in prevent-
ing new lesions. For the other entities in the follicular
occlusion tetrad, trauma does not appear to be a
major mechanism in the pathogenesis of these
conditions.
The patient’s smoking may also play a role in his
susceptibility to DSC. Nicotine may inhibit normal
glandular duct secretion and promote epithelial
hyperplasia and is hypothesized to play a role in
DSC and HS.10
Taken together, it is possible that interplay be-
tween interferon beta-1a therapy and smoking on a
background of multiple sclerosis favored the devel-
opment of DSC at the site of trauma. As we gain more
experience with the use of interferon beta-1a, it will
be important to evaluate if any of the entities that
comprise the follicular occlusion tetrad become
increasingly reported.
REFERENCES
1. Danby FW, Jemec GB, Marsch WCh, von Laffert M. Preliminary
findings suggest hidradenitis suppurativa may be due to
defective follicular support. Br J Dermatol. 2013;168:
1034-1039.
2. Giamarellos-Bourboulis EJ. Altered innate and adaptive
immune responses in patients with hidradenitis suppurativa.
Br J Dermatol. 2007;156:51-56.
3. Sukhatme SV, Lenzy YM, Gottlieb AB. Refractory dissecting
cellulitis of the scalp treated with adalimumab. J Drugs
Dermatol. 2008;7:981-983.
4. Wollina U, Gemmeke A, Koch A. Dissecting cellulitis of the
scalp responding to intravenous tumor necrosis factor-alpha
antagonist. J Clin Aesthet Dermatol. 2012;5:36-39.
5. van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA,
Laman JD, Prens EP. Elevated levels of tumor necrosis factor
(TNF)-a, interleukin (IL)-1b and IL-10 in hidradenitis suppu-
rativa skin: a rationale for targeting TNF-a, and IL-1b. Br J
Dermatol. 2011;164:1292-1298.
6. Lapins J, Asman B, Gustafsson A, Bergstr€om K, Emtestam L.
Neutrophil-related host response in hidradenitis suppurativa:
a pilot study in patients with inactive disease. Acta Derm
Venereol. 2001;81:96-99.
7. Study of possible correlation between hidradenitis and
rebif. Available at: http://factmed.com/study-REBIF-causing-
HIDRADENITIS.php. Accessed January 7, 2015.
8. Study of possible correlation between hidradenitis and
avonex. Available at: http://factmed.com/study-AVONEX-
causing-HIDRADENITIS.php. Accessed January 7, 2015.
9. Pironi D, Caruso F, Panarese A, et al. Chronic hidradenitis
suppurativa in the inguinal, perineal and scrotal regions. A
case report and review of the literature. Ann Ital Chir. 2010;81:
465-470.
10. Hana A, Booken D, Henrich C, et al. Functional significance of
non-neuronal acetylcholine in skin epithelia. Life Sci. 2007;
30(80):2214-2220.
